Across TCGA pan-cancer cohorts, KREMEN1 Mutation is linked to patient survival in 5 of 34 cancer types, making it the most broadly survival-associated KREMEN1 data layer compared with 1 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher KREMEN1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated KREMEN1 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LUSC, STAD, and HNSC are the cancer types where KREMEN1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	OS	Median	II,III,IV	0.181	0.742	.007	14	view →
STAD	OS	Median	II,III,IV	0.501	0.660	.006	10	view →
HNSC	OS	Median	All	0.185	0.685	.036	9	view →
LUAD	DFS	Median	All	0.152	0.771	<.001	9	view →
UCEC	OS	Median	All	1.000	0.667	.032	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: KREMEN1 tumor-vs-normal RNA expression · all KREMEN1 data types